Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control-Reference-Cited by-同舟云学术

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

Published:2023-03-28 Issue:12 Volume:329 Page:1024
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Lillegraven Siri¹,Paulshus Sundlisæter Nina¹,Aga Anna-Birgitte¹,Sexton Joseph¹,Solomon Daniel H.²,van der Heijde Désirée³,Haavardsholm Espen A.¹

Affiliation:

1. Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway

2. Division of Rheumatology, Brigham and Women’s Hospital, Boston, Massachusetts

3. Leiden University Medical Centre, Department of Rheumatology, Leiden, the Netherlands

Abstract

This open-label randomized clinical trial assessed the 12-month risk of disease activity flares after discontinuation of conventional synthetic DMARDs (csDMARDs) compared with continuing half-dose csDMARDs in adult Norwegian patients with rheumatoid arthritis and excellent disease control.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2802926/jama_lillegraven_2023_ld_230006_1683208317.74533.pdf

Reference5 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.;Smolen;Ann Rheum Dis,2023

2. Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the ARCTIC REWIND randomized clinical trial.;Lillegraven;JAMA,2021

3. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy.;Haschka;Ann Rheum Dis,2016

4. Treatment strategies for patients with immune-mediated inflammatory diseases.;Curtis;JAMA,2021

5. DMARD-free remission as novel treatment target in rheumatoid arthritis.;Verstappen;RMD Open,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial;The Lancet Rheumatology;2024-05

2. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial;Annals of the Rheumatic Diseases;2023-08-22

3. Incorrect Data in Table;JAMA;2023-05-09